A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART) Bi-specific Antibody-Based Molecule, in Healthy Subjects

Trial Profile

A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART) Bi-specific Antibody-Based Molecule, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs MGD 010 (Primary) ; Hepatitis A vaccine
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 17 Jun 2017 Results (n=24) presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results published in a MacroGenics media release.
    • 17 Jun 2017 According to a MacroGenics media release, updated data was presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top